Postmenopausal osteoporosis

Summary

Postmenopausal osteoporosis (MONDO:0008159) is a disease with 5 cohort genes and 120 clinical trials. Top therapeutic interventions include alendronic acid, teriparatide, and denosumab.

At a glance

• Cohort genes: 5
• ClinVar variants: 27
• Clinical trials: 120

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	postmenopausal osteoporosis
Mondo ID	MONDO:0008159
EFO	EFO:0003854
MeSH	D015663
ICD-11	123797893
SNOMED CT	102447009
UMLS	C0029458
MedGen	10498
Is cancer (heuristic)	no

Data availability: 27 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone remodeling disease › bone resorption disease › osteoporosis › postmenopausal osteoporosis

Related subtypes (6): nephrolithiasis/osteoporosis, hypophosphatemic, X-linked osteoporosis with fractures, idiopathic juvenile osteoporosis, drug-induced osteoporosis, pregnancy associated osteoporosis, premenopausal osteoporosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

27 retrieved; paginated sample, class counts are floors:

13 pathogenic, 9 conflicting classifications of pathogenicity, 3 pathogenic/likely pathogenic, 1 uncertain significance, 1 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
1074312	NM_000088.4(COL1A1):c.1614+1G>A	COL1A1	Pathogenic	criteria provided, multiple submitters, no conflicts
17312	NM_000088.4(COL1A1):c.994G>A (p.Gly332Arg)	COL1A1	Pathogenic	criteria provided, multiple submitters, no conflicts
17347	NM_000088.4(COL1A1):c.3040C>T (p.Arg1014Cys)	COL1A1	Pathogenic	criteria provided, multiple submitters, no conflicts
287320	NM_000088.4(COL1A1):c.2089C>T (p.Arg697Ter)	COL1A1	Pathogenic	criteria provided, multiple submitters, no conflicts
35925	NM_000088.4(COL1A1):c.579del (p.Gly194fs)	COL1A1	Pathogenic	criteria provided, multiple submitters, no conflicts
425580	NM_000088.4(COL1A1):c.1821+1G>A	COL1A1	Pathogenic	criteria provided, multiple submitters, no conflicts
425599	NM_000088.4(COL1A1):c.1299+1G>A	COL1A1	Pathogenic	criteria provided, multiple submitters, no conflicts
447141	NM_000088.4(COL1A1):c.2362G>A (p.Gly788Ser)	COL1A1	Pathogenic	criteria provided, multiple submitters, no conflicts
450546	NM_000088.4(COL1A1):c.985G>C (p.Gly329Arg)	COL1A1	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
17258	NM_000089.4(COL1A2):c.1981G>A (p.Gly661Ser)	COL1A2	Pathogenic	no assertion criteria provided
216908	NM_000089.4(COL1A2):c.3034G>A (p.Gly1012Ser)	COL1A2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
265387	NM_000089.4(COL1A2):c.577G>A (p.Gly193Ser)	COL1A2	Pathogenic	criteria provided, multiple submitters, no conflicts
456848	NM_000089.4(COL1A2):c.982G>A (p.Gly328Ser)	COL1A2	Pathogenic	criteria provided, multiple submitters, no conflicts
37143	NM_001025295.3(IFITM5):c.-14C>T	IFITM5	Pathogenic	criteria provided, multiple submitters, no conflicts
1179140	NM_002335.4(LRP5):c.2555C>T (p.Thr852Met)	LRP5	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
1172590	NM_005032.7(PLS3):c.1512-1G>T	PLS3	Pathogenic	criteria provided, single submitter
623483	NM_002335.4(LRP5):c.3758G>A (p.Cys1253Tyr)	LRP5	Likely pathogenic	no assertion criteria provided
324102	NM_000088.4(COL1A1):c.3233T>C (p.Val1078Ala)	COL1A1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
324103	NM_000088.4(COL1A1):c.3169G>A (p.Val1057Ile)	COL1A1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
388459	NM_000088.4(COL1A1):c.1375C>A (p.Pro459Thr)	COL1A1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
450185	NM_000088.4(COL1A1):c.4196G>A (p.Arg1399His)	COL1A1	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
17250	NM_000089.4(COL1A2):c.2123G>A (p.Arg708Gln)	COL1A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
281098	NM_000089.4(COL1A2):c.3047C>A (p.Pro1016His)	COL1A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
373178	NM_000089.4(COL1A2):c.3853A>C (p.Asn1285His)	COL1A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
526896	NM_000089.4(COL1A2):c.671G>A (p.Arg224His)	COL1A2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
183255	NM_002335.4(LRP5):c.3107G>A (p.Arg1036Gln)	LRP5	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
526891	NM_000089.4(COL1A2):c.52T>C (p.Cys18Arg)	COL1A2	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 29 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
IFITM5	Orphanet:216828	Osteogenesis imperfecta type 5
COL1A1	Orphanet:1310	Caffey disease
COL1A1	Orphanet:1899	Arthrochalasia Ehlers-Danlos syndrome
COL1A1	Orphanet:216796	Osteogenesis imperfecta type 1
COL1A1	Orphanet:216804	Osteogenesis imperfecta type 2
COL1A1	Orphanet:216812	Osteogenesis imperfecta type 3
COL1A1	Orphanet:216820	Osteogenesis imperfecta type 4
COL1A1	Orphanet:230857	Ehlers-Danlos/osteogenesis imperfecta syndrome
COL1A1	Orphanet:287	Classical Ehlers-Danlos syndrome
COL1A1	Orphanet:31112	Dermatofibrosarcoma protuberans
COL1A1	Orphanet:314029	High bone mass osteogenesis imperfecta
COL1A2	Orphanet:1899	Arthrochalasia Ehlers-Danlos syndrome
COL1A2	Orphanet:216796	Osteogenesis imperfecta type 1
COL1A2	Orphanet:216804	Osteogenesis imperfecta type 2
COL1A2	Orphanet:216812	Osteogenesis imperfecta type 3
COL1A2	Orphanet:216820	Osteogenesis imperfecta type 4
COL1A2	Orphanet:230851	Cardiac-valvular Ehlers-Danlos syndrome
COL1A2	Orphanet:230857	Ehlers-Danlos/osteogenesis imperfecta syndrome
COL1A2	Orphanet:314029	High bone mass osteogenesis imperfecta
LRP5	Orphanet:178377	Osteosclerosis-developmental delay-craniosynostosis syndrome
LRP5	Orphanet:2783	Autosomal dominant osteopetrosis type 1
LRP5	Orphanet:2788	Osteoporosis-pseudoglioma syndrome
LRP5	Orphanet:2790	Endosteal hyperostosis, Worth type
LRP5	Orphanet:2924	Isolated polycystic liver disease
LRP5	Orphanet:3416	Hyperostosis corticalis generalisata
LRP5	Orphanet:498481	LRP5-related primary osteoporosis
LRP5	Orphanet:891	Familial exudative vitreoretinopathy
LRP5	Orphanet:90050	Retinopathy of prematurity
PLS3	Orphanet:391330	X-linked osteoporosis with fractures

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
IFITM5	HGNC:16644	ENSG00000206013	A6NNB3	Interferon-induced transmembrane protein 5	clinvar
COL1A1	HGNC:2197	ENSG00000108821	P02452	Collagen alpha-1(I) chain	clinvar
COL1A2	HGNC:2198	ENSG00000164692	P08123	Collagen alpha-2(I) chain	clinvar
LRP5	HGNC:6697	ENSG00000162337	O75197	Low-density lipoprotein receptor-related protein 5	clinvar
PLS3	HGNC:9091	ENSG00000102024	P13797	Plastin-3	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
IFITM5	Interferon-induced transmembrane protein 5	Required for normal bone mineralization.
COL1A1	Collagen alpha-1(I) chain	Type I collagen is a member of group I collagen (fibrillar forming collagen).
COL1A2	Collagen alpha-2(I) chain	Type I collagen is a member of group I collagen (fibrillar forming collagen).
LRP5	Low-density lipoprotein receptor-related protein 5	Acts as a coreceptor with members of the frizzled family of seven-transmembrane spanning receptors to transduce signal by Wnt proteins.
PLS3	Plastin-3	Actin-bundling protein.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 5 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	5	1.8×	0.054

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
IFITM5	Other/Unknown	no		CD225/Dispanin_fam, IFITM_antiviral_protein
COL1A1	Other/Unknown	no		Fib_collagen_C, VWF_dom, Collagen
COL1A2	Other/Unknown	no		Fib_collagen_C, Collagen, Collagen_superfamily
LRP5	Other/Unknown	no		LDLR_classB_rpt, EGF, LDrepeatLR_classA_rpt
PLS3	Other/Unknown	no		Actinin_actin-bd_CS, CH_dom, EF_hand_dom

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
periodontal ligament	2
skin of hip	2
stromal cell of endometrium	2
blood	1
body of pancreas	1
granulocyte	1
ascending aorta	1
mucosa of transverse colon	1
right lobe of liver	1
blood vessel layer	1
calcaneal tendon	1
visceral pleura	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
IFITM5	83	tissue_specific	marker	body of pancreas, granulocyte, blood
COL1A1	298	ubiquitous	marker	stromal cell of endometrium, skin of hip, periodontal ligament
COL1A2	295	ubiquitous	marker	periodontal ligament, stromal cell of endometrium, skin of hip
LRP5	224	ubiquitous	marker	right lobe of liver, mucosa of transverse colon, ascending aorta
PLS3	297	ubiquitous	marker	blood vessel layer, calcaneal tendon, visceral pleura

Protein interactions among cohort

Intra-cohort edges: 3.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
COL1A1	5,341
LRP5	2,619
PLS3	2,295
IFITM5	835
COL1A2	179

Intra-cohort edges

A	B	Sources
COL1A1	COL1A2	intact
COL1A1	IFITM5	string_interaction
IFITM5	PLS3	string_interaction

Structural data

PDB: 3 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
COL1A1	P02452	14
PLS3	P13797	6
COL1A2	P08123	5

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
LRP5	O75197	78.65
IFITM5	A6NNB3	65.49

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 39. Enrichment computed across 5 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Defective VWF binding to collagen type I	2	2537.8×	4e-06	COL1A1, COL1A2
Enhanced cleavage of VWF variant by ADAMTS13	2	1903.3×	4e-06	COL1A1, COL1A2
Defective VWF cleavage by ADAMTS13 variant	2	1903.3×	4e-06	COL1A1, COL1A2
Enhanced binding of GP1BA variant to VWF multimer:collagen	2	1087.6×	8e-06	COL1A1, COL1A2
Defective binding of VWF variant to GPIb:IX:V	2	1087.6×	8e-06	COL1A1, COL1A2
GP1b-IX-V activation signalling	2	634.4×	2e-05	COL1A1, COL1A2
Anchoring fibril formation	2	507.6×	3e-05	COL1A1, COL1A2
Platelet Adhesion to exposed collagen	2	447.8×	3e-05	COL1A1, COL1A2
Scavenging by Class A Receptors	2	400.7×	3e-05	COL1A1, COL1A2
Fibronectin matrix formation	2	380.7×	3e-05	COL1A1, COL1A2
Crosslinking of collagen fibrils	2	380.7×	3e-05	COL1A1, COL1A2
Platelet Aggregation (Plug Formation)	2	292.8×	5e-05	COL1A1, COL1A2
Syndecan interactions	2	282.0×	5e-05	COL1A1, COL1A2
MET activates PTK2 signaling	2	253.8×	6e-05	COL1A1, COL1A2
GPVI-mediated activation cascade	2	205.8×	8e-05	COL1A1, COL1A2
Collagen chain trimerization	2	173.0×	1e-04	COL1A1, COL1A2
Developmental Lineage of Pancreatic Ductal Cells	2	152.3×	1e-04	COL1A1, COL1A2
Assembly of collagen fibrils and other multimeric structures	2	133.6×	2e-04	COL1A1, COL1A2
Collagen degradation	2	117.1×	2e-04	COL1A1, COL1A2
Collagen biosynthesis and modifying enzymes	2	113.6×	2e-04	COL1A1, COL1A2
Non-integrin membrane-ECM interactions	2	102.9×	2e-04	COL1A1, COL1A2
ECM proteoglycans	2	100.2×	2e-04	COL1A1, COL1A2
Integrin cell surface interactions	2	89.6×	3e-04	COL1A1, COL1A2
Cell surface interactions at the vascular wall	2	63.4×	5e-04	COL1A1, COL1A2
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	2	58.1×	6e-04	COL1A1, COL1A2
Signaling by LRP5 mutants	1	543.8×	0.003	LRP5
Signaling by RNF43 mutants	1	423.0×	0.003	LRP5
Negative regulation of TCF-dependent signaling by WNT ligand antagonists	1	237.9×	0.006	LRP5
Signaling by WNT in cancer	1	200.3×	0.007	LRP5
Regulation of FZD by ubiquitination	1	173.0×	0.007	LRP5

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
skin morphogenesis	2	561.7×	5e-04	COL1A1, COL1A2
bone morphogenesis	2	240.7×	0.001	IFITM5, LRP5
blood vessel development	2	149.8×	0.002	COL1A1, COL1A2
cellular response to amino acid stimulus	2	122.6×	0.003	COL1A1, COL1A2
bone mineralization	2	108.7×	0.003	IFITM5, COL1A2
collagen fibril organization	2	89.9×	0.003	COL1A1, COL1A2
regulation of blood pressure	2	88.7×	0.003	COL1A2, LRP5
protein heterotrimerization	1	3370.4×	0.003	COL1A2
cellular response to vitamin E	1	3370.4×	0.003	COL1A1
response to tacrolimus	1	1685.2×	0.005	IFITM5
cellular response to fluoride	1	1685.2×	0.005	COL1A1
skeletal system development	2	50.3×	0.005	COL1A1, COL1A2
tooth mineralization	1	1123.5×	0.006	COL1A1
cell-cell signaling involved in mammary gland development	1	1123.5×	0.006	LRP5
response to rapamycin	1	842.6×	0.007	IFITM5
mesodermal cell migration	1	674.1×	0.007	LRP5
extracellular matrix-cell signaling	1	674.1×	0.007	LRP5
anatomical structure regression	1	674.1×	0.007	LRP5
Norrin signaling pathway	1	674.1×	0.007	LRP5
cellular response to acetaldehyde	1	674.1×	0.007	COL1A1
intramembranous ossification	1	561.7×	0.008	COL1A1
apoptotic process involved in blood vessel morphogenesis	1	561.7×	0.008	LRP5
establishment of blood-retinal barrier	1	561.7×	0.008	LRP5
glucose catabolic process	1	481.5×	0.008	LRP5
cartilage development involved in endochondral bone morphogenesis	1	481.5×	0.008	COL1A1
retinal blood vessel morphogenesis	1	481.5×	0.008	LRP5
bone trabecula formation	1	421.3×	0.009	COL1A1
actin filament network formation	1	374.5×	0.009	PLS3
retina morphogenesis in camera-type eye	1	374.5×	0.009	LRP5
cell migration involved in gastrulation	1	306.4×	0.010	LRP5

Therapeutics

Drugs indicated for this disease

8 approved, 14 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Abaloparatide	Approved (phase 4)
Calcitonin Salmon	Approved (phase 4)
Denosumab	Approved (phase 4)
Estradiol	Approved (phase 4)
Estrogens, Conjugated	Approved (phase 4)
Parathyroid Hormone	Approved (phase 4)
Romosozumab	Approved (phase 4)
Teriparatide	Approved (phase 4)
Alendronic Acid	Phase 3 (in late-stage trials)
Alfacalcidol	Phase 3 (in late-stage trials)
Arzoxifene	Phase 3 (in late-stage trials)
Calcitonin	Phase 3 (in late-stage trials)
Calcium	Phase 3 (in late-stage trials)
Calcium Carbonate	Phase 3 (in late-stage trials)
Cholecalciferol	Phase 3 (in late-stage trials)
Ergocalciferol	Phase 3 (in late-stage trials)
Ibandronic Acid	Phase 3 (in late-stage trials)
Lidocaine	Phase 3 (in late-stage trials)
Menatetrenone	Phase 3 (in late-stage trials)
Odanacatib	Phase 3 (in late-stage trials)
Raloxifene	Phase 3 (in late-stage trials)
Risedronic Acid	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bazedoxifene, Deferasirox, Medronic Acid, Phytonadione, Sodium Fluoride, Teriparatide Acetate.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 5

Druggability breadth: 3 of 5 evidence-associated genes (60%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
IFITM5	0	0
COL1A1	0	0
COL1A2	0	0
LRP5	0	0
PLS3	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
COL1A1	8	Binding:8
COL1A2	4	Functional:4
LRP5	1	Binding:1

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	5	IFITM5, COL1A1, COL1A2, LRP5, PLS3

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
IFITM5	0	—
COL1A1	8	—
COL1A2	4	—
LRP5	1	—
PLS3	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 120.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	36
PHASE3	31
PHASE4	26
PHASE2	14
PHASE1	12
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05010590	PHASE4	ACTIVE_NOT_RECRUITING	Anabolic Therapy in Postmenopausal Osteoporosis
NCT05902078	PHASE4	RECRUITING	Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
NCT06767150	PHASE4	RECRUITING	StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
NCT06938152	PHASE4	RECRUITING	Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
NCT07406685	PHASE4	NOT_YET_RECRUITING	The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
NCT00079924	PHASE4	COMPLETED	Effects of Teriparatide in Postmenopausal Women With Osteoporosis
NCT00239629	PHASE4	COMPLETED	Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
NCT00545051	PHASE4	COMPLETED	A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
NCT00545363	PHASE4	COMPLETED	A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP)
NCT00545909	PHASE4	COMPLETED	BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
NCT00729651	PHASE4	COMPLETED	Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
NCT01544894	PHASE4	COMPLETED	Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
NCT01709110	PHASE4	COMPLETED	VERtebral Fracture Treatment Comparisons in Osteoporotic Women
NCT01750086	PHASE4	COMPLETED	Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
NCT02176382	PHASE4	COMPLETED	Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
NCT02499237	PHASE4	COMPLETED	Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
NCT02598440	PHASE4	COMPLETED	A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
NCT02598453	PHASE4	COMPLETED	PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
NCT02604836	PHASE4	COMPLETED	A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
NCT03472846	PHASE4	COMPLETED	MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
NCT04026256	PHASE4	COMPLETED	Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
NCT04719481	PHASE4	UNKNOWN	Pravastatin Reduces Acute Phase Response of Zoledronic Acid
NCT04719650	PHASE4	UNKNOWN	Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
NCT05630768	PHASE4	COMPLETED	Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women
NCT05645289	PHASE4	UNKNOWN	Efficacy and Safety of Minodronate in Patients With Low Back Pain
NCT06079476	PHASE4	COMPLETED	A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
NCT00091793	PHASE3	COMPLETED	Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis
NCT00092014	PHASE3	COMPLETED	A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
NCT00092027	PHASE3	COMPLETED	A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
NCT00092053	PHASE3	COMPLETED	Study of Investigational Drug in Osteoporosis (MK-0217-908)
NCT00165698	PHASE3	COMPLETED	Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women
NCT00247273	PHASE3	COMPLETED	A Study of Monthly Risedronate for Osteoporosis
NCT00358176	PHASE3	COMPLETED	Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
NCT00377819	PHASE3	COMPLETED	Study of Transitioning From Alendronate to Denosumab
NCT00529373	PHASE3	TERMINATED	A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
NCT00541658	PHASE3	COMPLETED	A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
NCT00577421	PHASE3	COMPLETED	Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
NCT00890981	PHASE3	COMPLETED	A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
NCT00909961	PHASE3	COMPLETED	A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
NCT00936897	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ALENDRONIC ACID	4	31
TERIPARATIDE	4	14
DENOSUMAB	4	10
ROMOSOZUMAB	4	8
IBANDRONIC ACID	4	7
RISEDRONIC ACID	4	7
ZOLEDRONIC ACID ANHYDROUS	4	6
CALCIUM CARBONATE	4	4
CALCIUM	4	3
ABALOPARATIDE	4	2
CALCITONIN SALMON	4	2
RALOXIFENE	4	2
STRONTIUM RANELATE	4	2
ALFACALCIDOL	4	1
BAZEDOXIFENE	4	1
CALCITRIOL	4	1
CHOLECALCIFEROL	4	1
DEFERASIROX	4	1
ERGOCALCIFEROL	4	1
MINODRONIC ACID	4	1
PRAVASTATIN	4	1
ODANACATIB	3	3
ELDECALCITOL	3	2
CLODRONATE DISODIUM	3	1
MENATETRENONE	3	1
ENCALERET SULFATE	2	1
CHEMBL5072826	0	3
CHEMBL4214483	0	3
CHEMBL4590044	0	2
CHEMBL4740172	0	1